Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance
Sign Up to like & getrecommendations! Published in 2019 at "Osteoporosis International"
DOI: 10.1007/s00198-019-05181-6
Abstract: Introduction In May 2013 and March 2014, the European Medicines Agency (EMA) issued two decisions restricting the use of strontium ranelate (SR). These risk minimisation measures (RMM) introduced new contraindications and limited the indications of… read more here.
Keywords: use strontium; minimisation measures; strontium ranelate; impact ... See more keywords